医学文献検索サービス -メディカルオンライン

アブストラクト

Title	No.7 副作用管理 : 皮膚障害
Subtitle	シリーズ : 抗がん薬治療の副作用
Authors	小澤有輝
Authors (kana)
Organization	一般財団法人神奈川県警友会けいゆう病院薬剤部
Journal	日本臨床腫瘍薬学会雑誌
Volume	23
Number
Page	1-13
Year/Month	2022 / 1
Article	報告
Publisher	日本臨床腫瘍薬学会
Abstract	「ポイント」・手足症候群の概要, 予防法, 治療法を理解する. ・EGFR阻害薬による皮膚障害の概要, 予防法, 治療法を理解する. ・タキサン系薬剤による爪障害の概要, 予防法, 治療法を理解する. ・その他, 皮膚障害の多い薬剤とその皮膚障害の特徴を理解する. 【はじめに】抗がん薬による皮膚障害は, 細胞障害性抗がん薬, 分子標的薬, 免疫チェックポイント阻害薬など様々なタイプの薬剤で発現し, その病態は多岐にわたる. 抗がん薬の皮膚障害は致死的となることは必ずしも多くはないが, 患者の日常生活動作(activities of daily living: ADL)や外観に影響を及ぼし, 生活の質(quality of life: QOL)を低下させることが知られている. また分子標的薬による皮膚障害の発現は, 治療効果と相関することが, 複数の薬剤で報告されており, 副作用の管理を適切に行い, 治療強度を維持することが重要である.
Practice	薬学
Keywords

全文ダウンロード：従量制、基本料金制の方共に770円(税込) です。

download全文ダウンロード(13.76MB)

参考文献

1) Wagner LI, et al.:The development of a Functional Assessment of Cancer Therapy(FACT) questionnaire to assess dermatologic symptoms associated with epidermal growth factor receptor inhibitors(FACTEGFRI-18), Support Care Cancer 2013;21(4):1033-1041.
pubmed
2) De Tursi M, et al.:Skin toxicity evaluation in patients treated with cetuximab for metastatic colorectal cancer:A new tool for more accurate comprehension of quality of life impacts, Onco Targets Ther 2017;10:3007-3015.
pubmed
3) Cunningham D, et al.:Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer, N Engl J Med 2004;351(4):337-345.
pubmed
4) Perez-Soler R:Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer, Clin Lung Cancer 2006;8(Suppl 1):S7-S14.
5) Kobayashi K, et al.:Association of Hand-Foot Skin Reaction with Regorafenib Efficacy in the Treatment of Metastatic Colorectal Cancer, Oncol 2019;96(4):200-206.

残りの57件を表示する

6) Lacouture ME, et al.:Prevention and management of dermatological toxicities related to anticancer agents:ESMO Clinical Practice Guidelines, Ann Oncol 2021;32(2):157-170.
pubmed
7) 重篤副作用疾患別対応マニュアル手足症候群厚生労働省;令和元年9月改定.
8) Ren ZG, et al.:Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma, J Clin Oncol 2015;33(8):894-900.
9) 志田敏宏, 他:マルチキナーゼ阻害薬の手足症候群発現に対する尿素軟膏およびヘパリン類似物質含有軟膏塗布による予防効果の比較, 日本病院薬剤師会雑誌. 2013;49:1293-1297.
10) Hofheinz RD, et al.:Mapisal versus urea cream as prophylaxis for capecitabine-associated hand-foot syndrome:A randomized phase III trial of the AIO quality of life working group, J Clin Oncol 2015;33(22):2444-2449.
11) 日本がんサポーティブケア学会:がん治療におけるアピアランスケアガイドライン第1版, 金原出版;2021.
12) Wolf SL, et al.:Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome:North central cancer treatment group study N05C5, J Clin Oncol 2010;28(35):5182-5187.
13) Ozawa Y, et al.:A case of adult T-cell leukemia/lymphoma with severe hand-foot syndrome during administration of modified LSG15 regimen, Gan TO Kagaku Ryoho 2020;47(10):1477-1480.
pubmed
14) Najjar YG, et al.:A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma, Eur J Cancer 2014;50(6):1084-1089.
pubmed
15) Bekaii-Saab TS, et al.:Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer(ReDOS):a randomised, multicentre, openlabel, phase 2 study, Lancet Oncol 2019;20(8):1070-1082.
pubmed
16) 有害事象共通用語規準v5.0 日本語訳JCOG版(CTCAE v5.0-JCOG) http://www.jcog.jp/doctor/tool/CTCAEv5J_20190905_v22_1.pdf
17) NCI-PRO-CTCAE(TM) ITEMS-JAPANESE Item Library Version 1.0 https://healthcaredelivery.cancer.gov/pro-ctcae/pro-ctcae_japanese.pdf
18) Blum BJL, et al.:Multicenter Phase II Study of Cape citabinein Paclitaxel-Refractory Metastatic Breast Cancer, J Clin Oncol 2016;17(2):485-493.
19) EGFR阻害薬・マルチキナーゼ阻害薬に起因する皮膚障害の治療手引き皮膚科・腫瘍内科有志コンセンサス会議からの提案, 臨床医薬. 2020;40:1315-1329.
20) 吉村知哲, 他:がん薬物療法副作用管理マニュアル第2版, 医学書院;2021.
21) Lacouture ME, et al.:Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities, Support Care Cancer 2011;19(8):1079-1095.
22) 土屋雅美:抗がん薬による皮膚障害とその対策, 医薬品相互作用研究. 2019;43(3):21-33.
23) Lacouture ME, et al.:Skin Toxicity Evaluation Protocol With Panitumumab(STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer, J Clin Oncol 2010;28(8):1351-1357.
24) Kobayashi Y, et al.:Randomized controlled trial on the skin toxicity of panitumumab in Japanese patients with metastatic colorectal cancer:HGCSG1001 study;J-STEPP, Future Oncol 2015;11(4):617-627.
pubmed
25) 日本皮膚科学会:尋常性ざ瘡治療ガイドライン2017, 2017;127(6):1261-1302.
26) 有田賢, 他:EGFR阻害剤関連の皮疹に対するロキシスロマイシンの効果, 皮の科. 2012;11(Suppl 19):1-3.
27) Nishino K, et al.:Results of the non-small cell lung cancer part of a phase III, open-label, randomized trial evaluating topical corticosteroid therapy for facial acneiform dermatitis induced by EGFR inhibitors:stepwise rank down from potent corticosteroid(FAEISS study, NCCH-1512), Support Care Cancer 2021;29(5):2327-2334.
pubmed
28) Robert C, et al.:Nail toxicities induced by systemic anticancer treatments, Lancet Oncol 2015;16(4):181-189.
29) Schepisi G, et al.:Taxane-related nail toxicity, Lancet Oncol 2015;16(7):310-311.
30) Atzori L, et al.:Drug Induced Onycholysis, Clin Dermatol J 2017;2(2):000114.
31) Gelderblom H, et al.:Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions, J Clin Oncol 2002;20(2):574-581.
pubmed
32) Huang KL, et al.:Prophylactic management for taxane-induced nail toxicity:A systematic review and meta-analysis, Eur J Cancer Care(Engl) 2019;11(5):e13118.
pubmed
33) Scotte F, et al.:Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand, J Clin Oncol 2005;23(19):4424-4429.
34) Ishiguro H, et al.:Degree of freezing does not affect efficacy of frozen gloves for prevention of docetaxel-induced nail toxicity in breast cancer patients, Support Care Cancer 2012;20(9):2017-2024.
35) Begon E, et al.:Frostbite as a complication of frozen gloves in the prevention of docetaxel-induced onycholysis, Eur J Dermatol 2011;21(4):628-629.
pubmed
36) Rusthoven JJ, et al.:Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer:A phase II study, J Clin Oncol 1999;17(4):1194-1199.
pubmed
37) Scagliotti GV, et al.:Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer, J Clin Oncol 2008;26(21):3543-3551.
pubmed
38) Hanna N, et al.:Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy, J Clin Oncol 2004;22(9):1589-1597.
pubmed
39) Vogelzang NJ, et al.:Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma, J Clin Oncol 2003;21(14):2636-2644.
pubmed
40) Thodtmann R, et al.:Clinical and pharmacokinetic phase I study of multitargeted antifolate(LY231514) in combination with cisplatin, J Clin Oncol 1999;17(10):3009-3016.
pubmed
41) Clarke SJ, et al.:Phase II trial of pemetrexed disodium(ALIMTA(R), LY231514) in chemotherapy-naive patients with advanced non-small-cell lung cancer, Ann Oncol 2002;13(5):737-741.
42) Ishikawa H, et al.:Effectiveness of steroids for the rash side effect of pemetrexed, Gan TO Kagaku Ryoho 2013;40(1):75-78.
pubmed
43) Chen YM, et al.:Maculopapular rashes secondary to gemcitabine injection for non-small-cell lung cancer, J Clin Oncol 1996;14(5):1743-1744.
pubmed
44) 杉山昌秀, 他:塩酸ゲムシタビンによる皮疹発現に関する検討, 日本病院薬剤師会雑誌. 2008;44(8):1237-1239.
Medical*Online
45) 下浦真一, 他:Gemcitabine(Gemzar)による薬疹当院における12 症例の検討, 日本皮膚科学会雑誌. 2009;119(6):1085-1089.
46) Tohyama M, et al.:Characteristic distribution of maculopapular rash caused by gemcitabine-based chemotherapy, J Dermatol 2021;48(2):215-218.
pubmed
47) Strouse C, et al.:A rash diagnosis:Gemcitabine-associated pseudocellulitis, J Oncol Pharm Pract 2017;23(2):157-160.
pubmed
48) Sibaud V, et al.:Dermatological adverse events with taxane chemotherapy, Eur J Dermatol 2016;26(5):427-443.
pubmed
49) 北澤文章, 他:デキサメタゾンの投与量が乳がん患者に対するドセタキセルおよびシクロホスファミド療法の皮膚毒性に及ぼす影響, 医療薬学. 2017;43(6):313-319.
Medical*Online
50) Watanabe K, et al.:Safety and tolerance of docetaxel(Especially 75 mg/m2) with cydophosphamide(TC Therapy) as adjuvant chemotherapy for Japanese patients with operable breast cancer, Gan TO Kagaku Ryoho 2010;37(7):1265-1269.
pubmed
51) 阿部圭輔, 他:乳がん患者に対して施行されたドセタキセル/シクロホスファミド療法時に発現した皮疹に対するデキサメタゾンの効果, 医療薬学. 2015;41(1):30-36.
Medical*Online
52) Rodriguez-Lomba E, et al.:Periarticular Thenar Erythema and Onycholysis Syndrome:A Manifestation of Taxane-Induced Cutaneous Toxicity, Actas Dermosifiliogr 2017;108(6):595-597.
pubmed
53) Miyaki T, et al.:Administration order of FECDOC in breast cancer adjuvant chemotherapy has an effect on toxicity, Gan TO Kagaku Ryoho 2015;42(5):1081-1085.
pubmed
54) 内田敬, 他:ドセタキセル投与患者の手に発現した皮膚障害と外的環境との関連, 日本臨床腫瘍薬学会雑誌. 2021;22:1-7.
Medical*Online
55) Kawaguchi K, et al.:Correlation between docetaxel-induced skin toxicity and use of steroid and H2 blocker:a multi-institution survery, Breast Cancer Res Treat 2011;130(2):627-634.
56) 末廣陽子:血液がんの新規抗腫瘍薬における皮膚障害-ベンダムスチンとモガムリズマブ, 医学のあゆみ. 2013;246(9):788-793.
Medical*Online
57) Alamdari HS, et al.:Severe cutaneous interface drug eruption associated with bendamustine, Dermatol Online J 2010;16(7):1.
pubmed
58) Uchida M, et al.:Risk factors for skin toxicities associated with bendamustine-based chemotherapy in patients with non-hodgkin lymphoma, Biol Pharm Bull 2020;43(10):1577-1582.
pubmed
59) Shikdar S, et al.:Presentation and management of the delayed type of hypersensitivity reaction with bendamustine, Anticancer Drugs 2018;29(8):814-816.
pubmed
60) Garcia CM, et al.:Successful bendamustine desensitization for a delayed-type hypersensitivity reaction, J Investig Allergol Clin Immunol 2019;29(1):68-69.
61) Carilli A, et al.:Severe dermatologic reactions with bendamustine:A case series, Case Rep Oncol 2014;7(2):465-470.
pubmed
62) 池末裕明:副作用管理:免疫関連有害事象(ir AE), 日本臨床腫瘍薬学会雑誌. 2020;17:11-19.

はじめての方へ

個人／法人会員登録のご案内